Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Hackensack Meridian Health
Novartis
University College, London
BeOne Medicines
University of Chicago
M.D. Anderson Cancer Center
University of Chicago
BeOne Medicines
Dana-Farber Cancer Institute
Eli Lilly and Company
Alliance for Clinical Trials in Oncology
University of Wisconsin, Madison
Massachusetts General Hospital
Roswell Park Cancer Institute
Incyte Corporation
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
Sanofi
Hoffmann-La Roche
Gilead Sciences
National Cancer Institute (NCI)
University of Washington
Incyte Corporation
BeiGene
Pfizer
City of Hope Medical Center
City of Hope Medical Center
Institut Bergonié
Universität des Saarlandes
Incyte Corporation
Insel Gruppe AG, University Hospital Bern
University of Washington
Incyte Corporation
Autolus Limited
International Extranodal Lymphoma Study Group (IELSG)
National Institutes of Health Clinical Center (CC)
Ipsen
Northwestern University
SWOG Cancer Research Network
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
University of Miami
BeiGene
Mayo Clinic
Ohio State University Comprehensive Cancer Center
Shattuck Labs, Inc.
Vanderbilt-Ingram Cancer Center
Gamida Cell ltd
National Cancer Institute (NCI)